Thursday 10 April saw the publication of the Cochrane systematic review on oseltamivir and zanamivir, or Tamiflu (Roche) and Relenza (GlaxoSmithKline) to give them their better-known trade names. In short, the review found that Tamiflu doesn’t work quite as well as we thought; a finding that is the culmination of a four-and-a-half year battle for access to the raw data from the clinical trials.
The authors – Jefferson, Heneghan and colleagues – uncovered what they characterized as ‘multisystem failure’, with poorly-defined endpoints and confusion as to the authorship and contribution of the clinical trials. They also found that all studies were conducted against placebo, rather than against current best practice. Overall, the reviewers felt that the published studies were ...Read more